Last reviewed 2026-04-20 · How we verify

Midamor (AMILORIDE)

Midamor (amiloride) is a potassium-sparing diuretic, a small molecule that targets the amiloride-sensitive sodium channel, ENaC. It was originally developed by Paddock LLC and is now owned by Padagis US. Midamor is used to treat edema, hypertensive disorders, and prevent hypokalemia. It was FDA-approved in 1981 and is now off-patent with multiple generic manufacturers. As a potassium-sparing diuretic, Midamor is a key consideration for patients with potassium imbalances.

At a glance

Approved indications

• Edema
• Hypertensive disorder
• Hypokalemia Prevention

Common side effects

• Headache
• Back pain
• Weakness
• Chest pain
• Fatigability
• Neck/shoulder ache
• Pain, extremities
• Nausea/anorexia
• Jaundice
• Diarrhea
• GI bleeding
• Vomiting

Drug interactions

• benazepril
• captopril
• enalapril
• eprosartan
• fosinopril
• irbesartan
• lisinopril
• losartan
• perindopril
• potassium acetate
• potassium chloride
• potassium citrate

Key clinical trials

• ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer (PHASE2)
• ENAC Blockade and Arterial Stiffness (PHASE2,PHASE3)
• Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura (PHASE2)
• Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene
• Comparison of Optimal Hypertension Regimens (PHASE4)
• Treatment of Vascular Stiffness in ADPKD (PHASE4)
• Mechanisms of Diuretic Resistance in Heart Failure, Aim 2 (PHASE1)
• Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.